Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
Journal of the International AIDS Society · 2024
DOI: 10.1002/jia2.26371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2024. Verfasst von Thierry Tiendrebeogo und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EM…. Hauptthemen laut MEDLINE: Pyridones, HIV Infections, Heterocyclic Compounds, 3-Ring, Oxazines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Introduction
Adverse metabolic effects related to dolutegravir (DTG) are increasingly reported as countries are adopting DTG‐based regimens as first‐line antiretroviral therapy (ART), but there is limited data from sub‐Saharan Africa. We explored changes in body weight pre‐ and post‐switch to a DTG‐based regimen and assessed the association between DTG switch and significant weight gain (SWG) defined as a ≥10% increase over a 12‐month period in people living with HIV (PLHIV) on ART in West Africa.
Methods
We first included all PLHIV followed in the IeDEA West Africa cohorts between January 2017 and June 2021, with a documented switch to DTG during 2019–2021 and in care ≥36 months at the day of switch. Weight change was estimated using a two slope piecewise linear mixed model with change point at the switch date. Secondly, we emulated a sequence of target trials (ETT) based on the observational data, performing pooled logistic regression analysis to compare SWG occurrence between PLHIV who switched to DTG and those who did not.
Results
We first included 6705 PLHIV from Burkina Faso, Côte d'Ivoire and Nigeria. Their median age at the time of switch was 48 years (IQR: 42–54) with a median follow‐up of 9 years (IQR: 6–12), 63% were female. Most patients switched from efavirenz (EFV)‐based ART (56.6%) and nevirapine (NVP)‐based ART (30.9%). The overall post‐switch annual average weight gain (AAWG) was significantly elevated at 3.07 kg/year [95% CI: 2.33–3.80] compared to the pre‐switch AWG which stood at 0.62 kg/year [95% CI: 0.36–0.88]. The post‐switch AWG was greater in patients previously on EFV and protease inhibitor (PI)‐based ART compared to those on NVP‐based ART. The pooled logistic regression analyses of a sequence of 24 ETT, including 9598 person‐trials, switching to DTG was significantly associated with an SWG (aOR = 2.54; 95% CI = 2.18–2.97).
Conclusions
In West Africa, a 12‐month DTG exposure was associated with substantial weight gain, especially in PLHIV previously on EFV and PI‐based ARTs. Continuous weight monitoring and metabolic profiling is imperative in HIV cohorts to delineate the long‐term cardiometabolic impact of DTG as patients with, or at elevated risk for cardiovascular diseases might benefit from alternative ART regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Research Centre, Bordeaux, France.
- Department of Infectious Diseases, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.
- Centre médical de Suivi des Donneurs de Sang (CMSDS), Centre National de Transfusion Sanguine Côte d'Ivoire (CNTSCI), Abidjan, Côte d'Ivoire.
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Office of the Central Secretariat, Nigeria Institute for Medical Research, Lagos, Nigeria.
- Département de Santé Publique, Université de Lomé, Lomé, Togo.
ORCID-Profile: Thierry Tiendrebeogo, Albert Minga
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAAA NIH HHS
- NIA NIH HHS
- FIC NIH HHS
- NIAID NIH HHS
- NIDA NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Tiendrebeogo, T., Malateste, K., Poda, A., Minga, A., Lahiri, C. D., Ezechi, O., Ekouevi, D. K., Ofotokun, I., Jaquet, A., & IeDEA West Africa Collaboration (2024). Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26371
Vancouver
Tiendrebeogo T, Malateste K, Poda A, Minga A, Lahiri CD, Ezechi O, et al. Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts. Journal of the International AIDS Society. 2024. doi:10.1002/jia2.26371
BibTeX
@article{Tiendrebeogo2024,
author = {Tiendrebeogo, Thierry and Malateste, Karen and Poda, Armel and Minga, Albert and Lahiri, Cecile D and Ezechi, Oliver and Ekouevi, Didier K and Ofotokun, Igho and Jaquet, Antoine and IeDEA West Africa Collaboration, IeDEA West Africa Collaboration},
title = {Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts},
journal = {Journal of the International AIDS Society},
year = {2024},
doi = {10.1002/jia2.26371}
}
EUVIMED